



Clinical trial results:

A Phase 3, Multicenter, Open-Label Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Subjects With Mild to Moderate Atopic Dermatitis (AD)

Summary

EudraCT number	2021-001266-38
Trial protocol	Outside EU/EEA
Global end of trial date	18 December 2020

Results information

Result version number	v1
This version publication date	30 June 2021
First version publication date	30 June 2021

Trial information

Trial identification

Sponsor protocol code	C3291027
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04498403
WHO universal trial number (UTN)	-
Other trial identifiers	JapicCTI: JapicCTI-205464

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 April 2021
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	18 December 2020
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To study the safety of crisaborole ointment, 2% applied twice daily (BID) in Japanese pediatric and adult subjects with mild to moderate AD

Protection of trial subjects:

The study was conducted in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 September 2020
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	1 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Japan: 40
Worldwide total number of subjects	40
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	22
Adolescents (12-17 years)	8
Adults (18-64 years)	10
From 65 to 84 years	0

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The study was conducted in Japan from 14 September 2020 to 18 December 2020. A total of 40 subjects were enrolled.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort 1: Crisaborole 2%, Age group: Less than (<) 18 Years

Arm description:

Subjects aged < 18 years with mild to moderate atopic dermatitis (AD) received crisaborole ointment, 2 percent (%) on treatable AD lesions, twice daily up to Week 52. Treatable AD lesions were identified at Baseline (Day 1) by investigator. Subjects were followed up to at least 28 days after last dose of study drug (up to Week 56).

Arm type	Experimental
Investigational medicinal product name	Crisaborole
Investigational medicinal product code	PF-06930164
Other name	
Pharmaceutical forms	Ointment
Routes of administration	Topical use

Dosage and administration details:

Subjects received crisaborole topical ointment, 2 % to treatment targeted lesions, twice daily up to Week 52.

Arm title	Cohort 2: Crisaborole 2%, Age group: >= 18 Years
------------------	--

Arm description:

Subjects aged greater than or equal to (>=) 18 years with mild to moderate AD received crisaborole ointment, 2 % on treatable AD lesions, twice daily up to Week 52. Treatable AD lesions were identified at Baseline (Day 1) by investigator. Subjects were followed up to at least 28 days after last dose of study drug (up to Week 56).

Arm type	Experimental
Investigational medicinal product name	Crisaborole
Investigational medicinal product code	PF-06930164
Other name	
Pharmaceutical forms	Ointment
Routes of administration	Topical use

Dosage and administration details:

Subjects received crisaborole topical ointment, 2 % to treatment targeted lesions, twice daily up to Week 52.

Number of subjects in period 1	Cohort 1: Crisaborole 2%, Age group: Less than ($<$) 18 Years	Cohort 2: Crisaborole 2%, Age group: \geq 18 Years
Started	30	10
Completed Follow up	30	10
Completed	0	0
Not completed	30	10
Adverse event, non-fatal	1	-
Study Terminated By Sponsor	29	10

Baseline characteristics

Reporting groups

Reporting group title	Cohort 1: Crisaborole 2%, Age group: Less than (<) 18 Years
-----------------------	---

Reporting group description:

Subjects aged < 18 years with mild to moderate atopic dermatitis (AD) received crisaborole ointment, 2 percent (%) on treatable AD lesions, twice daily up to Week 52. Treatable AD lesions were identified at Baseline (Day 1) by investigator. Subjects were followed up to at least 28 days after last dose of study drug (up to Week 56).

Reporting group title	Cohort 2: Crisaborole 2%, Age group: >= 18 Years
-----------------------	--

Reporting group description:

Subjects aged greater than or equal to (>=) 18 years with mild to moderate AD received crisaborole ointment, 2 % on treatable AD lesions, twice daily up to Week 52. Treatable AD lesions were identified at Baseline (Day 1) by investigator. Subjects were followed up to at least 28 days after last dose of study drug (up to Week 56).

Reporting group values	Cohort 1: Crisaborole 2%, Age group: Less than (<) 18 Years	Cohort 2: Crisaborole 2%, Age group: >= 18 Years	Total
Number of subjects	30	10	40
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	22	0	22
Adolescents (12-17 years)	8	0	8
Adults (18-64 years)	0	10	10
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	9.3	31.8	
standard deviation	± 3.99	± 7.97	-
Sex: Female, Male Units: Subject			
Female	15	4	19
Male	15	6	21
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	30	10	40
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	0	0	0
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB)			

Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	30	10	40
Unknown or Not Reported	0	0	0

End points

End points reporting groups

Reporting group title	Cohort 1: Crisaborole 2%, Age group: Less than (<) 18 Years
Reporting group description: Subjects aged < 18 years with mild to moderate atopic dermatitis (AD) received crisaborole ointment, 2 percent (%) on treatable AD lesions, twice daily up to Week 52. Treatable AD lesions were identified at Baseline (Day 1) by investigator. Subjects were followed up to at least 28 days after last dose of study drug (up to Week 56).	
Reporting group title	Cohort 2: Crisaborole 2%, Age group: >= 18 Years
Reporting group description: Subjects aged greater than or equal to (>=) 18 years with mild to moderate AD received crisaborole ointment, 2 % on treatable AD lesions, twice daily up to Week 52. Treatable AD lesions were identified at Baseline (Day 1) by investigator. Subjects were followed up to at least 28 days after last dose of study drug (up to Week 56).	

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) ^[1]
End point description: An adverse events (AE) is any untoward medical occurrence in clinical investigation subject administered a product or medical device; event need not necessarily to have a causal relationship with treatment or usage. SAEs: an AE resulting in any of following outcomes/deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are events between first dose of study drug and up to 28 days after last dose of study drug, that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events. Safety population included all subjects who took at least 1 dose of study drug.	
End point type	Primary
End point timeframe: Baseline (Day 1) up to at least 28 days after last dose of investigational product (up to Week 56)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analyzed for this endpoint.

End point values	Cohort 1: Crisaborole 2%, Age group: Less than (<) 18 Years	Cohort 2: Crisaborole 2%, Age group: >= 18 Years		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	10		
Units: Subjects				
TEAEs	11	3		
SAEs	0	0		

Statistical analyses

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline (Day 1) up to at least 28 days after last dose of investigational product (up to Week 56)

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

Reporting groups

Reporting group title	Cohort 1: Crisaborole 2%, Age group: Less than (<) 18 Years
-----------------------	---

Reporting group description:

Subjects aged < 18 years with mild to moderate AD received crisaborole ointment, 2% on treatable AD lesions, twice daily up to Week 52. Treatable AD lesions were identified at Baseline (Day 1) by investigator. Subjects were followed up to at least 28 days after last dose of study drug (up to Week 56).

Reporting group title	Cohort 2: Crisaborole 2%, Age group: >= 18 Years
-----------------------	--

Reporting group description:

Subjects aged >= 18 years with mild to moderate AD received crisaborole ointment, 2 % on treatable AD lesions, twice daily up to Week 52. Treatable AD lesions were identified at Baseline (Day 1) by investigator. Subjects were followed up to at least 28 days after last dose of study drug (up to Week 56).

Serious adverse events	Cohort 1: Crisaborole 2%, Age group: Less than (<) 18 Years	Cohort 2: Crisaborole 2%, Age group: >= 18 Years	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 30 (0.00%)	0 / 10 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Cohort 1: Crisaborole 2%, Age group: Less than (<) 18 Years	Cohort 2: Crisaborole 2%, Age group: >= 18 Years	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 30 (36.67%)	3 / 10 (30.00%)	
Injury, poisoning and procedural complications			
Wound			
subjects affected / exposed	0 / 30 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	

General disorders and administration site conditions			
Application site pain			
subjects affected / exposed	1 / 30 (3.33%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	1 / 30 (3.33%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Dermatitis atopic			
subjects affected / exposed	2 / 30 (6.67%)	0 / 10 (0.00%)	
occurrences (all)	2	0	
Dermatitis contact			
subjects affected / exposed	1 / 30 (3.33%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Joint effusion			
subjects affected / exposed	0 / 30 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 30 (3.33%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Gastroenteritis			
subjects affected / exposed	0 / 30 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Molluscum contagiosum			
subjects affected / exposed	1 / 30 (3.33%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Nasopharyngitis			
subjects affected / exposed	3 / 30 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	5	0	
Otitis media acute			
subjects affected / exposed	1 / 30 (3.33%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Rhinitis			

subjects affected / exposed	1 / 30 (3.33%)	0 / 10 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported